Production (Stage)
Cue Biopharma, Inc.
CUE
$0.602
-$0.0337-5.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.99M | 9.29M | 9.53M | 8.30M | 7.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.99M | 9.29M | 9.53M | 8.30M | 7.02M |
| Cost of Revenue | 35.44M | 37.09M | 40.80M | 41.29M | 42.41M |
| Gross Profit | -27.45M | -27.81M | -31.27M | -32.99M | -35.39M |
| SG&A Expenses | 13.77M | 13.79M | 14.37M | 15.15M | 15.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.21M | 50.88M | 55.17M | 56.44M | 58.30M |
| Operating Income | -41.22M | -41.59M | -45.64M | -48.15M | -51.28M |
| Income Before Tax | -40.58M | -40.67M | -44.61M | -46.96M | -49.97M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.58 | -40.67 | -44.61 | -46.96 | -49.97 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.58M | -40.67M | -44.61M | -46.96M | -49.97M |
| EBIT | -41.22M | -41.59M | -45.64M | -48.15M | -51.28M |
| EBITDA | -40.82M | -41.20M | -45.23M | -47.70M | -50.80M |
| EPS Basic | -0.66 | -0.75 | -0.91 | -0.97 | -1.07 |
| Normalized Basic EPS | -0.42 | -0.47 | -0.57 | -0.61 | -0.66 |
| EPS Diluted | -0.66 | -0.75 | -0.91 | -0.97 | -1.07 |
| Normalized Diluted EPS | -0.42 | -0.47 | -0.57 | -0.61 | -0.66 |
| Average Basic Shares Outstanding | 249.90M | 225.11M | 198.07M | 193.20M | 187.82M |
| Average Diluted Shares Outstanding | 249.90M | 225.11M | 198.07M | 193.20M | 187.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |